Back

Outcomes of subcutaneous implantable cardioverter defibrillators: UK tertiary centre experience

7 April 2024 (08:30 - 15:00)
Organised by: Logo
Congress Presentation Part of: Poster session on devices, others Implantable Cardioverter-Defibrillator (ICD) EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Lin-Thiri Toon

University Hospital Southampton, Southampton (United Kingdom of Great Britain & Northern Ireland)

108 More presentations in this session

Presentation thumbnail
Emergency leadless pacing implantation is feasible and safe out-of-hours
Doctor F. O'Rourke (London, GB)
Abstract Slides Video
Presentation thumbnail
Evaluation of the quality of life of patients with leadless pacing system during 1 year follow-up period
Doctor A. Baimbetov (Almaty, KZ)
Abstract Slides
Presentation thumbnail
Which paced QRS duration can be achieved in selective and non-selective His bundle pacing?
Mr C. Israel (Bielefeld, DE)
Abstract Slides Video
Presentation thumbnail
Procedural heart rate variability and its effect on short-term symptoms after cardioneuromodulation procedure
Doctor S. AYGUN (Ankara, TR)
Abstract
Presentation thumbnail
Depression and anxiety in Greek heart failure patients who received a cardiac resynchronization therapy device and did not receive shock therapy during a 12-month follow-up
Professor P. Korantzopoulos (Ioannina, GR)
Abstract

Access the full session

Session thumbnail
Poster session on devices, others

The Event

Event poster

EHRA 2024

7 April - 9 April 2024
You may be interested in
thumbnail
Congress Presentation
The safety and feasibility of same-day discharge after subcutaneous implantable cardioverter defibrillator implantation
thumbnail
Congress Presentation
Subcutaneous versus transvenous implantable cardioverter-defibrillator therapy: real world data from a Portuguese cohort
thumbnail
Congress Presentation
long term follow up of Implantable Cardioverter Defibrillators (ICD) in hypertrophic cardiomyopathy: is subcutaneous the way forward?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources